Liver Disease Diagnostics and Treatment Market Size, Share and Global Trend By Treatment ( Anti-Viral Drugs, Vaccines, Chemotherapy, Targeted Therapy, Immunosuppressant, Immunoglobulins), By Diagnosis (Imaging, mLaboratory Tests, Endoscopy, Biopsy, Others), By End User (Hospitals, Clinics, Diagnostic Laboratories, Others), and Regional Forecast, 2024-2032

The liver is a vital organ which mainly functions to metabolize and detoxify the toxic substances that could be harmful to the body. Liver disease refers to any disease condition that results in liver inflammation and may disturb the proper functioning of the liver. The causes for liver diseases are an infection, autoimmune diseases, overconsumption of over the counter drugs, injury, alcohol consumption, and others.

Liver disease includes liver cancer, hepatitis A, hepatitis B, Non-alcoholic fatty liver disease, cirrhosis, hemochromatosis, and many others. According to the American Cancer Society projections, the new cases of primary liver cancer and intrahepatic bile duct cancer in the United States for 2018 will be above 30,610 in males and 11,610 in females. Growing prevalence of hepatitis, A & B infections, growing obesity, and rising unmet clinical need in liver disease are likely to boost the growth of liver disease diagnostics and treatment market during the forecast period.

The global liver disease diagnostics and treatment market growth is being driven by the increase in the prevalence of liver cancer, alcohol consumption, health reimbursement for liver cancer and heavy intake of over the counter high dosage drugs. Other factors which are likely to boost the growth of global liver disease diagnostics and treatment market are the presence of strong pipeline drugs for the treatment of fatty liver disease and growing key mergers and acquisitions among many key players.

For example, in October 2018, Novartis AG collaborated with Pfizer Inc., to initiate clinical study combining tropifexor, including an Acetyl CoA-Carboxylase (ACC) Inhibitor, and a Ketohexokinase (KHK) Inhibitor for the treatment of non-alcoholic steatohepatitis (NASH).

However, side effects and risks associated with the usage of medications involved for the treatment of liver disease and the stringent government regulations are expected to hinder the growth in global liver disease diagnostics and treatment market during the forecast period.

 Key Players Covered

Some of the major companies that are present in the global liver disease diagnostics and treatment market report include Pfizer Inc., Novartis AG, Abbott, Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Mylan N.V., among others.

SEGMENTATION

As per the global liver disease diagnostics and treatment market trends, imaging segment, among diagnosis segment, is anticipated to hold the largest share in global liver disease diagnostics and treatment market owing to the growing demand for non-invasive imaging techniques and growing technological advancements in liver disease imaging techniques.

Key Insights

• Pipeline Analysis of Liver Disease Drugs


• Overview of Epidemiology of Liver Cancer


• The Regulatory Scenario of Key Country/Region


• Recent Key Industry Developments – Mergers, Acquisitions, and Partnerships.

Regional Analysis

The global liver disease diagnostics and treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is anticipated to dominate the global liver disease diagnostics and treatment market owing to increasing adoption of novel diagnostic and therapeutic approaches for the treatment of liver disease, growing prevalence liver disease, and increase in the unmet need. Asia. Asia Pacific is anticipated to register significant CAGR in global liver disease diagnostics and treatment market during the forecast period owing to a growing patient population and growing investments in R&D by many key players & government organizations.

Liver Disease Diagnostics and Treatment Industry Developments 

• In January 2019, SciCann Therapeutics launched a liver disease program in Tel Aviv University which was mainly designed to explore the efficacy of SciCann’s line of proprietary, cannabinoid-based, anti-inflammatory combination products for the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)
• In October 2018, Novartis AG collaborated with Pfizer Inc., to initiate clinical study combining tropifexor, including an Acetyl CoA-Carboxylase (ACC) Inhibitor, and a Ketohexokinase (KHK) Inhibitor for the treatment of non-alcoholic steatohepatitis (NASH).